Immune responses targeting homocitrullinated peptides drive rheumatoid arthritis-like pathology in HLA-DR4 transgenic mice.

OBJECTIVES

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterised by persistent synovial inflammation and progressive joint destruction. A hallmark feature of RA is the presence of anti-citrullinated protein autoantibodies (ACPAs), which have been extensively studied in disease pathogenesis. The development of these autoantibodies is strongly associated with the expression of HLA-DR4, containing the shared epitope. More recently, anti-homocitrullinated protein autoantibodies (AHCPAs) have also been implicated in RA and demonstrate a similar genetic association. Therefore, this study aimed to evaluate the role of homocitrulline immune responses in RA pathogenesis.

METHODS

HLA-DR4 transgenic (DR4tg) and C57Bl/6 (B6) mice were immunised with a synthetic homocitrullinated peptide (HomoCitJED) or PBS followed by a booster 21 days later. Beginning on day 75 post-primary immunisation mice received knee intra-articular (i.a.) injections of HomoCitJED once a week for three consecutive weeks. Swelling post i.a. injection was measured using digital calipers. IgG antibodies against citrullinated/homocitrullinated peptides/proteins were measured using enzyme-linked immunosorbent assay (ELISA). Knees were sectioned and analysed for histopathological damage and citrullinated/homocitrullinated protein levels.

RESULTS

HomoCitJED immunised DR4tg mice exhibited significantly greater swelling and incidence of anti-HomoCitJED and anti-homocitrullinated fibrinogen IgG autoantibodies. Additionally, 30% had responses against CitJED, a synthetic citrullinated peptide. HomoCitJED immunised DR4tg mice also experienced greater total histopathological damage; however, the immunisations/injections did not affect citrullinated/homocitrullinated protein levels in the joint.

CONCLUSIONS

Homocitrulline-specific immune responses can induce RA-like disease in DR4tg mice, supporting the pathogenic role of AHCPAs in RA.